Today’s close was quiet in Africa, and we have left it that way rather than force older stories into the feed. The global transactions were more revealing than noisy: capital was used to buy development rights, market access, minority influence, public ownership and industrial capacity, often without buying full control.
Novartis signs a rights-led RNA deal with Abogen
Novartis signed a licensing agreement with China’s Abogen worth up to US$7.8 billion. US$575 million is payable upfront; the rest depends on development and regulatory milestones. Novartis is buying exclusive rights to one RNA therapy and options over others, not buying the company.
Mynt prices its GCash IPO
Mynt priced its GCash IPO at PHP6.60 a share. The base offer could raise PHP53 billion, about US$845 million, with a greenshoe taking the total to PHP60.9 billion. The mix of primary and secondary shares means the transaction is doing two jobs: funding the company and creating liquidity for existing owners.
Italgas agrees to acquire 22.5% of Floene
Italgas agreed to pay about €120 million for 22.5% of Portugal’s Floene. This is market entry through a minority position rather than a control acquisition. The economics will depend on governance, information rights and alignment with Allianz, which retains 75%.
Generali agrees to buy 9.9% of Banco de Crédito Cooperativo
Generali agreed to buy 9.9% of Banco de Crédito Cooperativo for €150 million. The stake is small in ownership terms, but strategically useful if it strengthens access to the cooperative bank’s distribution network.
Shyam Metalics signs a planned US$5.19 billion Maharashtra investment
Shyam Metalics signed an agreement to invest about US$5.19 billion in a steel plant in Maharashtra. The important distinction is status: this is an investment framework, not capital already financed and deployed. Land, approvals, utilities, financing and construction still determine whether the announcement becomes an operating asset.
What the structure tells us
Today’s structures are a reminder that control is only one reason to transact. Novartis wants scientific rights, Italgas and Generali want strategic positions, and Mynt is using the market for both growth capital and shareholder liquidity.
The useful question is not simply who bought what. It is what capability, access, ownership outcome or future option the structure is meant to secure, and whether the economics still work if the hoped-for next stage takes longer than planned.
M&A · IPO · Minority investment · Licensing · Industrial investment